InMed Pharmaceuticals Inc

InMed Pharmaceuticals Inc a clinical stage pharmaceutical company researches and develops cannabinoidbased therapies The companys lead product is INM755 a cannabinol topical cream which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa The company is also involved in developing INM088 which is in preclinical studies for the treatment of glaucoma and INM405 for the treatment of pain In addition it engages in the development of cannabinoidbased treatments for various diseases including dermatology and ocular diseases Further the company works on INDenabling pharmacology and preclinical toxicology studies and IntegraSyn an integrated biosynthesisbased manufacturing approach for synthesizing pharmaceuticalgrade cannabinoids It has a research collaboration agreement with BayMedica Inc for the manufacturing and testing of novel cannabinoid therapeutics The company was formerly known as Cannabis Technologies Inc and changed its name to InMed Pharmaceuticals Inc in October 2014 InMed Pharmaceuticals Inc was incorporated in 1981 and is headquartered in Vancouver Canada